General Information of Drug (ID: DM196LK)

Drug Name
MI-219 Drug Info
Synonyms
CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide
Indication
Disease Entry ICD 11 Status REF
Triple negative breast cancer 2C60-2C65 Investigative [1]
Cross-matching ID
PubChem CID
24877503
TTD Drug ID
DM196LK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7388 DMF5GZI Acute myeloid leukaemia 2A60 Phase 3 [2]
APG-115 DMIFA0L Prolymphocytic leukaemia 2A82.1 Phase 2 [3]
ALRN-6924 DMLBWT1 Haematological malignancy 2B33.Y Phase 2 [3]
AMG 232 DM65PTO Merkel cell carcinoma 2C34 Phase 2 [4]
ASTX295 DM9EM5G Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
HDM201 DMVRTCW Haematological malignancy 2B33.Y Phase 1 [3]
DS-3032 DMA2B5Y Haematological malignancy 2B33.Y Phase 1 [6]
RG7775 DMXBS6U Acute myeloid leukaemia 2A60 Phase 1 [7]
JNJ-26854165 DMNSJ3C Non-small-cell lung cancer 2C25.Y Phase 1 [8]
BI 907828 DM2Z4YQ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ubiquitin-protein ligase E3 Mdm2 (MDM2) TT08GJW MDM2_HUMAN Inhibitor [1]

References

1 MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.
2 Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41.
5 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
6 Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36.
7 Phase I clinical trail of RG7775 for treating Acute myelogenous leukemia. Roche.
8 Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.
9 MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874.